2026-09-19 · 2026-09 / week-3
Surgery Partners’ $797 million sale removes revenue before it removes the leverage risk
Surgery Partners’ $797 million sale removes revenue before it removes the leverage risk
Summary: Surgery Partners completed the sale of its Idaho Falls facilities to Intermountain Health for $797 million gross and $587 million net cash proceeds on September 17. The same release cut 2026 guidance to $3.08–$3.18 billion revenue and at least $489 million adjusted EBITDA, from the prior $3.35–$3.45 billion and $530 million-plus outlook. The short case is a smaller operating base with leverage still to reconcile; the counterpoint is that cash proceeds can reduce debt and improve payer mix. At the latest completed regular-session reference of $13.25 on September 18, a base short target of $11.50 clears 10%, but a credible recovery to $16.50 is a 24.53% adverse rise and the gross reward-to-adverse-risk ratio is 0.71:1. This is a no-trade short screen, not an executable recommendation. The paired signal is watch, with entry.price: null and execution.can_execute: false.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Surgery Partners (SGRY) | Short | Divestiture cuts revenue and EBITDA while debt and pro-forma cash are not yet reconciled | Sep. 17 closing 8-K, Aug. 10 Q2 results, Sep. 18 close | Post-sale debt, payer mix and next filing | 12.95M shares short, 10.10% float, 4.7 DTC as of Aug. 31 | Reject: base -13.21%, adverse +24.53%, ratio 0.71:1 | Liquid common stock; live borrow and depth unverified | $587M net cash proceeds can delever and improve the remaining business |
| 2 | XCharge (XCH) | Short | H1 contraction versus H2 delivery guide | Sep. 18 H1 results, Sep. 18 close | H2 deliveries | Already screened in prior run | Excluded as duplicate | Extremely thin | Scheduled deliveries and thin-float gaps |
| 3 | Nucor (NUE) | Short | Q3 guide below consensus versus steel-price support | Sep. 17 guide, Sep. 18 close | Oct. 26 results | Already screened in prior run | Excluded as duplicate | Liquid | Steel spread and cash generation |
Selected opportunity: Surgery Partners, for information value only.
Why this one now: The transaction is closed, so the evidence boundary is materially new. The headline cash proceeds are real, but the equity question is not “did Surgery sell an asset?” It is whether the remaining portfolio’s lower earnings base, reduced payer exposure and debt burden create enough per-share downside after the proceeds are applied.
What should surprise the reader: A divestiture can be both strategically positive and a short-term equity warning. The sale reduces Idaho Falls exposure and brings cash, but it also removes a large revenue and EBITDA contribution; the remaining debt, interest and pro-forma share count decide who actually benefits.
Why This Is the Best Opportunity Right Now
Surgery Partners’ September 17 release says it completed the Idaho Falls sale for $797 million gross proceeds and $587 million net cash proceeds. Full-year 2026 guidance is now $3.08–$3.18 billion revenue and at least $489 million adjusted EBITDA. On a full-year pro forma basis excluding Idaho Falls, management guides to $2.60–$2.67 billion revenue and at least $414 million adjusted EBITDA. Surgery Partners sale and updated guidance
Before the sale, Q2 results showed $216.7 million cash, $617.8 million of revolver capacity, $125.2 million adjusted EBITDA and a $15 million net loss. The company’s 2025 annual report describes approximately $3.7 billion aggregate indebtedness. Surgery Partners Q2 results, 2025 annual report
Why This Can Move More Than 5% Soon
SGRY closed at $13.25 on September 18 after a $12.97–$13.49 range and 2.76 million shares. The next observable tests are debt repayment, interest savings, pro-forma payer mix, remaining facility utilization and whether the $587 million net proceeds actually improve equity cash flow. SGRY price history
10/5 Asymmetry Gate
| Input | Result |
|---|---|
| Reference price | $13.25 regular-session close, Sep. 18, 2026 |
| Base short target | $11.50 |
| Base decline | -13.21% |
| Credible adverse target | $16.50 |
| Adverse rise | +24.53% |
| Gross reward / adverse risk | 0.71:1 |
| Probability-weighted expected short return | +3.35% before costs |
| 10/5 status | Reject |
The base clears 10%, but the adverse path is well above 5% and the ratio fails. The sale proceeds could create a positive deleveraging surprise before the next filing.
The Setup
The short screen tests whether the market is treating the sale as an uncomplicated cash unlock while the operating base contracts and debt remains uncertain. The counterparty case is strong: $587 million net cash can pay down debt, reduce interest and remove a lower-quality Idaho market, potentially improving the remaining portfolio’s growth and payer mix.
The Market Price
The model uses the September 18 regular-session close of $13.25. Current spread, depth, venue quality, borrow, recall and exit liquidity were not verified.
The Mispricing
Fact: revenue guidance fell from $3.35–$3.45B to $3.08–$3.18B and adjusted EBITDA guidance from at least $530M to at least $489M. Fact: $587M net cash proceeds were received. Inference: the equity must be priced on both lower earnings and the debt/cash deployment bridge, not on the sale headline alone.
The market may be right if proceeds materially reduce leverage and the remaining outpatient portfolio produces better margins. It may be wrong if debt, interest and facility obligations consume the proceeds while the smaller business loses scale.
The Positioning
As of August 31, third-party FINRA-derived data show 12.95 million shares short, 10.10% of float and 4.7 days to cover, up 2.39% from the prior report. That is meaningful positioning and raises squeeze risk after any debt-paydown disclosure. SGRY short interest
The Catalyst
- Verify net proceeds, taxes, transaction adjustments and debt repayment.
- Reconcile pro-forma revenue and EBITDA with remaining facility count and payer mix.
- Test interest expense, cash flow and covenant headroom after closing.
- Re-price only after a completed regular session and live short mechanics.
Price Target and Probability Map
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 25% | $9.00 | -32.08% | Through next filing | Proceeds fail to offset debt and remaining EBITDA weakens | Low |
| Base Case | 50% | $11.50 | -13.21% | Through next filing | Smaller base and debt bridge remain unresolved | Medium |
| Bottom Case | 25% | $16.50 | +24.53% | Same window | Deleveraging, payer improvement and squeeze | Medium |
| Invalidation | n/a | Debt and interest fall with stable pro-forma EBITDA | Thesis invalidated | Before entry | Primary filing proves per-share cash improvement | High |
Probability-weighted expected value: $12.77, equivalent to a +3.35% expected short return before costs.
Current market level and timestamp: $13.25 regular-session close, September 18, 2026.
Primary instrument: SGRY common stock, unlevered.
10/5 favorable base move: -13.21% underlying decline.
10/5 credible adverse move: +24.53% underlying rise.
10/5 measurement basis: verified regular-session close reference; not an executable entry.
10/5 status: Reject.
Confidence: Medium. The sale and guidance are primary, but debt application, pro-forma cash flow and live short mechanics remain incomplete.
The Kill Shot
The strongest counterparty argument is that $587 million of net cash can materially delever the company, lower interest expense and improve the quality of the remaining outpatient platform. The load-bearing assumption in the short is that the lower earnings base and leverage burden remain more important than the cash proceeds.
What Could Go Wrong
Debt repayment, lower interest, payer-mix improvement, stronger same-facility cases, buybacks, a squeeze from 10% float short and a gap through any stop can defeat the short. A five-percent stop cannot protect against a post-closing cash surprise.
What Would Prove This Wrong
The short thesis is wrong if Surgery reports debt reduction, lower interest, stable pro-forma EBITDA, improved payer mix and positive cash conversion after the sale. The sale headline alone is not enough either way.
Risk Audit
- Evidence: the closing release and prior Q2/annual filings are primary; price and positioning are third-party market data.
- Positioning: 10.10% float short and 4.7 DTC create squeeze risk.
- Execution:
entry.priceis null andexecution.can_executeis false. No options, leverage, margin, market order or no-locate short is permitted. - Model: probabilities are analyst estimates; the adverse case is 24.53%.
Best Trade Strategy
No trade. Re-open after a primary post-sale balance-sheet and pro-forma earnings bridge with verified locate, borrow, recall, spread, depth, settlement and exit-liquidity data.
Sources
- Surgery Partners sale and updated guidance, September 17, 2026.
- Surgery Partners Q2 2026 results, August 10, 2026.
- Surgery Partners 2025 annual report, filed March 2026.
- SGRY price history, September 18, 2026 close.
- SGRY short interest, August 31, 2026 settlement.
- XCharge H1 2026 results, candidate source.
- Nucor Q3 guidance, candidate source.
Research Quality Scorecard
| Criterion | Score | Reason |
|---|---|---|
| Market disagreement | 5/5 | Lower operating base versus a concrete cash/deleveraging bridge |
| Evidence base | 5/5 | Fresh closing release plus Q2 and annual primary filings |
| Positioning and flows | 4/5 | 10.10% float short and 4.7 DTC; live flow data missing |
| Catalyst path | 5/5 | Debt, interest, payer mix and cash tests are observable |
| Payoff architecture | 2/5 | Base clears 10%, but adverse risk and ratio fail |
| Invalidation discipline | 5/5 | Pro-forma debt, EBITDA and cash are monitorable |
| Differentiated insight | 4/5 | Divestiture is positive strategically but can shrink earnings faster than leverage |
| Client value | 5/5 | Prevents mistaking sale proceeds for per-share value |
Total: 35/40. The evidence supports a useful post-transaction screen, but the failed 10/5 gate forces Reject/no-trade.
Bottom Line
Surgery Partners received $587 million net cash, but the Idaho Falls sale also reduced 2026 guidance to $3.08–$3.18B revenue and at least $489M EBITDA. At $13.25, the base decline to $11.50 clears 10%, yet a recovery to $16.50 is a 24.53% adverse path and the ratio is only 0.71:1. Keep the entry null.
AI Illustration Prompt
Editorial financial illustration: a surgical hospital wing being separated from a larger healthcare network, a closing ledger marked “$797M GROSS / $587M NET CASH,” a second ledger showing “GUIDANCE $3.08–$3.18B REVENUE / EBITDA $489M+,” and debt documents waiting for repayment; hospital-blue, graphite, paper white and controlled amber, documentary realism, no trading interface, no price prediction; subtle readable “The Mispricing Desk” watermark.